The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The phase I study of concurrent chemoradiotherapy using a combination of gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer: Update.
 
Tatsuya Ioka
Consulting or Advisory Role - AstraZeneca; Baxalta; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Merck Serono
 
Kazuhiro Katayama
Speakers' Bureau - Ajinomoto; Bayer; Gilead Sciences; Otsuka; Otsuka
Research Funding - Bayer (Inst); Eisai (Inst); Kirin Pharmaceuticals (Inst); Kowa (Inst); Nobelpharma (Inst); Otsuka (Inst); Yakult Honsha (Inst)
 
Ryoji Takada
No Relationships to Disclose
 
Kazuyoshi Ohkawa
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline
Research Funding - Lilly (Inst); MSD (Inst)
 
Hidenori Takahashi
Speakers' Bureau - Daiichi Sankyo; Novartis; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Teruki Teshima
No Relationships to Disclose